STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
2024 Activity Report – Brazil
Estimação do impacto de diferentes cenários de redução do consumo de álcool no…
Estimation of the impact of various scenarios of reduction of alcohol use in…
Relatório de Atividades 2024 – Brasil
The Future of Health Financing in Africa: The Role of Health Taxes
RESET Alcohol Initiative Case Study: Media Campaign Resonates with the Public in Mexico
RESET Alcohol Initiative Case Study: A Historic Win for Alcohol Policy in Brazil
Effects of Heat on Early Childhood Development
Blood Lead Surveillance of Children and Pregnant Women in Tamil Nadu, India
Sportswashing through Media: Coca-Cola’s Olympic Play – A Research Report